Q3 EPS Forecast for Caribou Biosciences Boosted by Analyst

Caribou Biosciences, Inc. (NASDAQ:CRBU) – Investment analysts at Brookline Capital Management increased their Q3 2025 earnings estimates for shares of Caribou Biosciences in a research report issued to clients and investors on Tuesday, August 12th. Brookline Capital Management analyst L. Cann now expects that the company will post earnings of ($0.36) per share for the quarter, up from their previous estimate of ($0.38). The consensus estimate for Caribou Biosciences’ current full-year earnings is ($1.64) per share. Brookline Capital Management also issued estimates for Caribou Biosciences’ Q4 2025 earnings at ($0.41) EPS, FY2025 earnings at ($1.42) EPS, FY2026 earnings at ($0.97) EPS, FY2027 earnings at ($1.41) EPS and FY2028 earnings at $2.02 EPS.

Several other research analysts have also recently weighed in on the stock. HC Wainwright reissued a “buy” rating and set a $3.00 price target (down previously from $9.00) on shares of Caribou Biosciences in a research report on Monday, April 28th. Wall Street Zen cut shares of Caribou Biosciences from a “hold” rating to a “sell” rating in a research report on Saturday.

Caribou Biosciences Trading Down 1.0%

Shares of CRBU stock opened at $1.98 on Friday. The company’s 50-day moving average price is $1.67 and its 200-day moving average price is $1.25. The stock has a market cap of $184.38 million, a price-to-earnings ratio of -1.11 and a beta of 2.55. Caribou Biosciences has a twelve month low of $0.66 and a twelve month high of $3.00.

Caribou Biosciences (NASDAQ:CRBU) last announced its quarterly earnings results on Tuesday, August 12th. The company reported ($0.35) earnings per share for the quarter, beating the consensus estimate of ($0.40) by $0.05. The firm had revenue of $2.67 million for the quarter, compared to analysts’ expectations of $1.64 million. Caribou Biosciences had a negative net margin of 1,800.93% and a negative return on equity of 62.35%.

Institutional Trading of Caribou Biosciences

Institutional investors and hedge funds have recently bought and sold shares of the stock. Next Capital Management LLC purchased a new stake in Caribou Biosciences in the 2nd quarter valued at about $25,000. Creative Planning purchased a new stake in Caribou Biosciences in the 2nd quarter valued at about $25,000. Hudson Bay Capital Management LP purchased a new stake in Caribou Biosciences in the 2nd quarter valued at about $30,000. Savant Capital LLC purchased a new stake in Caribou Biosciences in the 2nd quarter valued at about $36,000. Finally, Cerity Partners LLC raised its holdings in Caribou Biosciences by 163.6% in the 1st quarter. Cerity Partners LLC now owns 40,722 shares of the company’s stock valued at $37,000 after buying an additional 25,271 shares during the period. 77.51% of the stock is currently owned by hedge funds and other institutional investors.

About Caribou Biosciences

Caribou Biosciences, Inc, a clinical-stage biopharmaceutical company, engages in the development of genome-edited allogeneic cell therapies for the treatment of hematologic malignancies in the United States and internationally. Its lead product candidate is CB-010, an allogeneic anti-CD19 CAR-T cell therapy that is in phase 1 clinical trial to treat relapsed or refractory B cell non-Hodgkin lymphoma.